In the subgroup of patients with primary biliary cirrhosis  , ursodeoxycholic acid  reduced total cholesterol ( WMD : − 29.86 mg/dL , 95 % CI : -47.39 , − 12.33 , p = 0.001 ) and LDL-C ( WMD : -37.27 mg/dL , 95 % CI : -54.16 , − 20.38 , p < 0.001 ) concentrations without affecting TG and HDL-C. Conclusion This meta- analysis suggests that ursodeoxycholic acid therapy might be associated with significant total cholesterol lowering particularly in patients with primary biliary cirrhosis
Objective The aim of this meta- analysis of r and omized placebo-controlled trials was to examine whether ursodeoxycholic acid treatment is an effective lipid-lowering agent .
A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid.
BACKGROUND / AIMS Ursodeoxycholic acid ( UDCA ) and colchicine have beneficial effects in primary biliary cirrhosis ( PBC ) . The efficacy of colchicine and UDCA in PBC was compared in a 2-year  placebo-controlled study ( n = 90 ) . METHODS Clinical events , laboratory test results , and liver histology were recorded at the beginning and end of the trial . RESULTS There were significantly fewer dropouts for hepatic reasons with UDCA than with placebo .  Pruritus was reduced by both active drugs . Colchicine improved liver function test results only modestly , whereas UDCA significantly decreased the serum activities of aminotransferases , alkaline phosphatase , and gamma-glutamyltransferase compared with colchicine and placebo .  Serum total bilirubin levels were decreased only by UDCA . Both colchicine and UDCA reduced serum cholesterol levels , and UDCA also reduced high-density lipoprotein cholesterol levels . Furthermore , UDCA reduced the serum levels of immunoglobulin ( Ig ) M and IgG , and colchicine reduced IgG levels compared with placebo . The elevated serum level of aminoterminal propeptide of type III procollagen remained unchanged by colchicine or UDCA , whereas the serum level of carboxyterminal propeptide of type I procollagen was significantly decreased by UDCA . UDCA significantly decreased ductular proliferation compared with colchicine or placebo . CONCLUSIONS These data suggest that UDCA frequently is superior to colchicine and especially to placebo in the treatment of PBC
In the subgroup of patients with primary biliary cirrhosis  , ursodeoxycholic acid  reduced total cholesterol ( WMD : − 29.86 mg/dL , 95 % CI : -47.39 , − 12.33 , p = 0.001 ) and LDL-C ( WMD : -37.27 mg/dL , 95 % CI : -54.16 , − 20.38 , p < 0.001 ) concentrations without affecting TG and HDL-C. Conclusion This meta- analysis suggests that ursodeoxycholic acid therapy might be associated with significant total cholesterol lowering particularly in patients with primary biliary cirrhosis
Objective The aim of this meta- analysis of r and omized placebo-controlled trials was to examine whether ursodeoxycholic acid treatment is an effective lipid-lowering agent .